Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib to Reactivate HIV and Reduce HIV Reservoir Size
NCT07881809Phase 2Not yet recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Nov 2026
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
A Phase 2 trial of ixazomib in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
ixazomib
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07881809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07881809.